News

JFK Airport Chooses LOGIPIX for Airside Virtual Ramp Control System

JFK Millennium Partners, the consortium leading a $4.2 billion redevelopment at JFK International Airport, has selected LOGIPIX US Corporation to implement an advanced Virtual Ramp Control System at the new JFK Terminal 6. This pioneering technology promises to revolutionize airport operations by enhancing security, efficiency, and safety on the ground.

LOGIPIX, a global leader in high-resolution intelligent computer vision solutions, was chosen after a rigorous selection process for its advanced capabilities and track record of successful implementations in high-volume commercial airside environments, such as LaGuardia Airport.

The Virtual Ramp Control System will leverage LOGIPIX’ innovative multi-sensor panoramic video technology and Airside Augmented Reality Solution (LAARS) software to provide monitoring and analysis of ground activities with live object classification and tracking, supporting the Terminal 6 gate operations center. Integrating high-resolution cameras, intelligent AI analytics, and advanced control features, the system will enhance the efficiency of aircraft management with real time decision-making support and improved situational awareness.

“We are thrilled to work with JFK Millennium Partners to deploy our Virtual Ramp Control System,” said Mike Broggie, President of LOGIPIX US Corporation. “This collaboration underscores our commitment to provide cutting-edge solutions that address the evolving needs of modern airports, and we are confident that our technology will contribute to JFK’s innovative transformation into a world-class facility.”

Implementation of the Virtual Ramp Control System will occur in two phases during construction of Terminal 6.

Recent News

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and

09/14/2026

BRAINBox Solutions Announces Agreement with Prolight Diagnostics for Commercial Supply of Pyros® Devices for Delivery of BRAINBox Concussion Diagnostics/Prognostics at Point-of-Care

BRAINBox Solutions announced it has entered into an agreement with Prolight Diagnostics to supply its Psyros® instruments and cartridges for use in point-of-care (PoC) delivery of BRAINBox’s TBI diagnostic/prognostic tests for concussion (also known as mTBI or Acute Traumatic Encephalopathy). “This agreement is an important step towards commercialization of our solutions and reflects the successful